Bristol-Myers Squibb
Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.
BMY Key Statistics
Stock Snapshot
With a market cap of 125.51B, Bristol-Myers Squibb(BMY) trades at $61.68. The stock has a price-to-earnings ratio of 13.75 and currently yields dividends of 4.02%.
On 2026-10-01, Bristol-Myers Squibb(BMY) stock traded between a low of $61.25 and a high of $62.61. Shares are currently priced at $61.68, which is +0.7% above the low and -1.5% below the high.
Bristol-Myers Squibb(BMY) shares are trading with a volume of 10.77M, against a daily average of 15.68M.
During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.
During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.
BMY News
Bristol Myers Squibb: Slow and Steady Revenue Growth Bristol Myers Squibb (BMY -1.23%) operates as a global biopharmaceutical entity that researches, develops,...
BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb yesterday and set a price target of $60.00. Evan Seigerman has given his Hol...
Bristol Myers (BMY) announced the expansion of Champions in Care, the company’s initiative honoring healthcare professionals, or HCPs, first launched in 2025. A...
Analyst ratings
58%
of 31 ratingsMore BMY News
...
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb (BMY) has completed a real‑world study titled “Tre...
Investing Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric Bristol Myers Squibb has raised its dividend for 17 straight ye...
Bristol-Myers Squibb (NYSE:BMY) reported the first Phase 3 EXCALIBER-RRMM results for ZENBEXUS in relapsed or refractory multiple myeloma. The pivotal trial sh...
In recent weeks, Bristol-Myers Squibb reported two-year Phase 3 POETYK PsA-2 data for Sotyktu in psoriatic arthritis, expanded access to ZENBEXUS through a rest...
Bristol-Myers Squibb, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn from Morgan Stanley maintained a Sell r...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.